These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
221 related articles for article (PubMed ID: 25700835)
1. Evaluation of absolute and normalized apparent diffusion coefficient (ADC) values within the post-operative T2/FLAIR volume as adverse prognostic indicators in glioblastoma. Elson A; Bovi J; Siker M; Schultz C; Paulson E J Neurooncol; 2015 May; 122(3):549-58. PubMed ID: 25700835 [TBL] [Abstract][Full Text] [Related]
2. Apparent diffusion coefficient and tumor volume measurements help stratify progression-free survival of bevacizumab-treated patients with recurrent glioblastoma multiforme. Buemi F; Guzzardi G; Del Sette B; Sponghini AP; Matheoud R; Soligo E; Trisoglio A; Carriero A; Stecco A Neuroradiol J; 2019 Aug; 32(4):241-249. PubMed ID: 31066622 [TBL] [Abstract][Full Text] [Related]
3. Evaluation of pre-radiotherapy apparent diffusion coefficient (ADC): patterns of recurrence and survival outcomes analysis in patients treated for glioblastoma multiforme. Elson A; Paulson E; Bovi J; Siker M; Schultz C; Laviolette PS J Neurooncol; 2015 May; 123(1):179-88. PubMed ID: 25894597 [TBL] [Abstract][Full Text] [Related]
4. Comparison of ADC metrics and their association with outcome for patients with newly diagnosed glioblastoma being treated with radiation therapy, temozolomide, erlotinib and bevacizumab. Wen Q; Jalilian L; Lupo JM; Molinaro AM; Chang SM; Clarke J; Prados M; Nelson SJ J Neurooncol; 2015 Jan; 121(2):331-9. PubMed ID: 25351579 [TBL] [Abstract][Full Text] [Related]
6. Pre-treatment MRI minimum apparent diffusion coefficient value is a potential prognostic imaging biomarker in cervical cancer patients treated with definitive chemoradiation. Marconi DG; Fregnani JH; Rossini RR; Netto AK; Lucchesi FR; Tsunoda AT; Kamrava M BMC Cancer; 2016 Jul; 16():556. PubMed ID: 27469349 [TBL] [Abstract][Full Text] [Related]
7. Clinical parameters outweigh diffusion- and perfusion-derived MRI parameters in predicting survival in newly diagnosed glioblastoma. Burth S; Kickingereder P; Eidel O; Tichy D; Bonekamp D; Weberling L; Wick A; Löw S; Hertenstein A; Nowosielski M; Schlemmer HP; Wick W; Bendszus M; Radbruch A Neuro Oncol; 2016 Dec; 18(12):1673-1679. PubMed ID: 27298312 [TBL] [Abstract][Full Text] [Related]
8. Large-volume low apparent diffusion coefficient lesions predict poor survival in bevacizumab-treated glioblastoma patients. Zhang M; Gulotta B; Thomas A; Kaley T; Karimi S; Gavrilovic I; Woo KM; Zhang Z; Arevalo-Perez J; Holodny AI; Rosenblum M; Young RJ Neuro Oncol; 2016 May; 18(5):735-43. PubMed ID: 26538618 [TBL] [Abstract][Full Text] [Related]
9. Histogram analysis of apparent diffusion coefficient within enhancing and nonenhancing tumor volumes in recurrent glioblastoma patients treated with bevacizumab. Rahman R; Hamdan A; Zweifler R; Jiang H; Norden AD; Reardon DA; Mukundan S; Wen PY; Huang RY J Neurooncol; 2014 Aug; 119(1):149-58. PubMed ID: 24805151 [TBL] [Abstract][Full Text] [Related]
10. Apparent diffusion coefficient histogram metrics correlate with survival in diffuse intrinsic pontine glioma: a report from the Pediatric Brain Tumor Consortium. Poussaint TY; Vajapeyam S; Ricci KI; Panigrahy A; Kocak M; Kun LE; Boyett JM; Pollack IF; Fouladi M Neuro Oncol; 2016 May; 18(5):725-34. PubMed ID: 26487690 [TBL] [Abstract][Full Text] [Related]
11. Apparent diffusion coefficient histogram analysis stratifies progression-free and overall survival in patients with recurrent GBM treated with bevacizumab: a multi-center study. Pope WB; Qiao XJ; Kim HJ; Lai A; Nghiemphu P; Xue X; Ellingson BM; Schiff D; Aregawi D; Cha S; Puduvalli VK; Wu J; Yung WK; Young GS; Vredenburgh J; Barboriak D; Abrey LE; Mikkelsen T; Jain R; Paleologos NA; Lada P; Prados M; Goldin J; Wen PY; Cloughesy T J Neurooncol; 2012 Jul; 108(3):491-8. PubMed ID: 22426926 [TBL] [Abstract][Full Text] [Related]
12. Pre-Operative Perfusion Skewness and Kurtosis Are Potential Predictors of Progression-Free Survival after Partial Resection of Newly Diagnosed Glioblastoma. Paik W; Kim HS; Choi CG; Kim SJ Korean J Radiol; 2016; 17(1):117-26. PubMed ID: 26798224 [TBL] [Abstract][Full Text] [Related]
13. Recurrent glioblastoma multiforme: ADC histogram analysis predicts response to bevacizumab treatment. Pope WB; Kim HJ; Huo J; Alger J; Brown MS; Gjertson D; Sai V; Young JR; Tekchandani L; Cloughesy T; Mischel PS; Lai A; Nghiemphu P; Rahmanuddin S; Goldin J Radiology; 2009 Jul; 252(1):182-9. PubMed ID: 19561256 [TBL] [Abstract][Full Text] [Related]
14. Correlation of apparent diffusion coefficient values measured by diffusion MRI and MGMT promoter methylation semiquantitatively analyzed with MS-MLPA in patients with glioblastoma multiforme. Sunwoo L; Choi SH; Park CK; Kim JW; Yi KS; Lee WJ; Yoon TJ; Song SW; Kim JE; Kim JY; Kim TM; Lee SH; Kim JH; Sohn CH; Park SH; Kim IH; Chang KH J Magn Reson Imaging; 2013 Feb; 37(2):351-8. PubMed ID: 23023975 [TBL] [Abstract][Full Text] [Related]
16. Serial analysis of imaging parameters in patients with newly diagnosed glioblastoma multiforme. Li Y; Lupo JM; Polley MY; Crane JC; Bian W; Cha S; Chang S; Nelson SJ Neuro Oncol; 2011 May; 13(5):546-57. PubMed ID: 21297128 [TBL] [Abstract][Full Text] [Related]
17. Dynamics of FLAIR Volume Changes in Glioblastoma and Prediction of Survival. Grossman R; Shimony N; Shir D; Gonen T; Sitt R; Kimchi TJ; Harosh CB; Ram Z Ann Surg Oncol; 2017 Mar; 24(3):794-800. PubMed ID: 27766560 [TBL] [Abstract][Full Text] [Related]
18. A Predictor of Tumor Recurrence in Patients With Endometrial Carcinoma After Complete Resection of the Tumor: The Role of Pretreatment Apparent Diffusion Coefficient. Kuwahara R; Kido A; Tanaka S; Abiko K; Nakao K; Himoto Y; Nishio N; Kurata Y; Mandai M; Togashi K Int J Gynecol Cancer; 2018 Jun; 28(5):861-868. PubMed ID: 29683878 [TBL] [Abstract][Full Text] [Related]
19. Graded functional diffusion map-defined characteristics of apparent diffusion coefficients predict overall survival in recurrent glioblastoma treated with bevacizumab. Ellingson BM; Cloughesy TF; Lai A; Mischel PS; Nghiemphu PL; Lalezari S; Schmainda KM; Pope WB Neuro Oncol; 2011 Oct; 13(10):1151-61. PubMed ID: 21856685 [TBL] [Abstract][Full Text] [Related]